Of note, “on-target off-tumor” toxicity against healthy FLT3+ cells were indeed observed with FLT3xCD3 bispecific antibodies that stimulate T cells, as well as with CAR-T cells; for both, such low target antigen levels are sufficient to induce activation [12,38,39]. This evidence concerns the gene FLT3 and neoplasm.